Skip to main content
SpringerLink
Log in

Management of Glycopeptide-Resistant Staphylococcus aureus Infections

  • Chapter
Book cover Management of Multiple Drug-Resistant Infections

Part of the book series: Infectious Disease ((ID))

  • 138 Accesses

Abstract

Before the introduction of penicillin, invasive Staphylococcus aureus infections were associated with mortality rates over 90% (1). Although penicillin was initially effective, resistance because of β-lactamase appeared quickly and spread. Within 10 yr, strains were resistant to erythromycin, tetracycline, and chloramphenicol. Methicillin resistance associated with modified penicillin-binding proteins (PBPs) appeared within 2 yr of the introduction of methicillin (2), and over the subsequent decades, strains resistant to an increasing number of antibiotics have spread worldwide. In hospitals, S. aureus resistant to multiple antibiotics commonly exceeds the susceptible strains. The emergence of glycopeptide-intermediate S. aureus (GISA) and vancomycin-resistant S. aureus (VRSA) raised the possibility of infections untreatable by standard antibiotic combinations. New agents are under investigation, but few fulfill the role.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith IM, Vickers AB. Natural history of 338 treated and untreated patients with staphylococcal septicaemia. Lancet 1960; 1: 1318 - 1321.

    Article  PubMed  CAS  Google Scholar 

  2. Jevons MP. “Celbenin” resistant staphylococci. BMJ 1961; 1:124-125.

    Google Scholar 

  3. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association. J Hosp Infect 1998; 39:253-290.

    Google Scholar 

  4. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50 - 55.

    Article  PubMed  CAS  Google Scholar 

  5. Pujol M, Pena C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996; 100: 509 - 516.

    Article  PubMed  CAS  Google Scholar 

  6. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995; 21: 1417 - 1423.

    Article  PubMed  CAS  Google Scholar 

  7. Bayer AS. Infective endocarditis. Clin Infect Dis 1993; 17:313-320, quiz 321-322.

    Google Scholar 

  8. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995; 274: 1706 - 1713.

    CAS  Google Scholar 

  9. Liu CY, Lee WS, Fung CP, et al. Comparative study of teicoplanin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Drug Invest 1996; 12: 80 - 87.

    Article  CAS  Google Scholar 

  10. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147 - 155.

    Article  PubMed  CAS  Google Scholar 

  11. Linares J. The VISA/GISA problem: therapeutic implications. Clin Microbiol Infect 2001; 7 (suppl. 4): 8 - 15.

    Article  PubMed  Google Scholar 

  12. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670 1673.

    Google Scholar 

  13. Ike Y, Arakawa Y, Ma X, et al. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol 2001; 39: 4445 - 4451.

    Article  PubMed  CAS  Google Scholar 

  14. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet 1998; 351: 602.

    Article  PubMed  CAS  Google Scholar 

  15. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72: 195 - 198.

    Article  PubMed  CAS  Google Scholar 

  16. Staphylococcus aureus resistant to vancomycin-United States. MMWR Morb Mortal Wkly Rep 2002; 51:565-567.

    Google Scholar 

  17. Miller D, Uredaneta V, Weltman A. Vancomycin-resistant Staphylococcus aureus-Pennsylvania 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 902.

    Google Scholar 

  18. National Committee for Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved Standard M7-A5. 5th ed. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.

    Google Scholar 

  19. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108 - 115.

    Article  PubMed  CAS  Google Scholar 

  20. Bobin-Dubreux S, Reverdy ME, Nervi C, et al. Clinical isolate of vancomycinheterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother 2001; 45: 349 - 352.

    Article  PubMed  CAS  Google Scholar 

  21. Arthur M, Reynolds PE, Depardieu F, et al. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996; 32: 11 - 16.

    Article  PubMed  CAS  Google Scholar 

  22. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and ß-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999; 43: 1747 - 1753.

    PubMed  CAS  Google Scholar 

  23. Moreira B, Boyle-Vavra S, deJonge BL, Daum RS. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997; 41: 1788 - 1793.

    PubMed  CAS  Google Scholar 

  24. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587 - 1588.

    Article  PubMed  CAS  Google Scholar 

  25. Nicolaou KC, Hughes R, Cho SY, Winssinger N, Labischinski H, Endermann R. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycinresistant bacteria: target-accelerated combinatorial synthesis. Chemistry 2001; 7: 3824 - 3843.

    Article  PubMed  CAS  Google Scholar 

  26. Aeschlimann JR, Allen GP, Hershberger E, Rybak MJ. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob Agents Chemother 2000; 44: 2991 - 2998.

    Article  PubMed  CAS  Google Scholar 

  27. Schentag JJ. Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Crit Care Med 2001; 29 (4 suppl.): N100 - N107.

    Article  PubMed  CAS  Google Scholar 

  28. Burnie J, Matthews R, Jiman-Fatami A, Gottardello P, Hodgetts S, DArcy S. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000; 31: 684 - 689.

    Article  PubMed  CAS  Google Scholar 

  29. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493 - 501.

    Article  PubMed  CAS  Google Scholar 

  30. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135 - 136.

    Article  PubMed  CAS  Google Scholar 

  31. Backo M, Gaenger E, Burkart A, Chai YL, Bayer AS. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam. Antimicrob Agents Chemother 1999; 43: 2565 - 2568.

    PubMed  CAS  Google Scholar 

  32. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179: 2557 - 2566.

    PubMed  CAS  Google Scholar 

  33. Howe RA, Wootton M, Bennett PM, MacGowan AP, Walsh TR. Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility. J Clin Microbiol 1999; 37: 3068 - 3071.

    PubMed  CAS  Google Scholar 

  34. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against etaphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062 - 1066.

    Article  PubMed  CAS  Google Scholar 

  35. Hershberger E, Aeschlimann JR, Moldovan T, Rybak MJ. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrob Agents Chemother 1999; 43: 717 - 721.

    PubMed  CAS  Google Scholar 

  36. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481 - 1490.

    Article  PubMed  CAS  Google Scholar 

  37. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207 - 208.

    Article  PubMed  CAS  Google Scholar 

  38. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020 - 1027.

    PubMed  CAS  Google Scholar 

  39. Vouillamoz J, Tomasz A, Sieradzki K, et al. Efficacy of Synercid (SYN) and/or cefpirome (CP) in the treatment (Rx) of experimental endocarditis (EE) due to glycopeptide intermediate Staphylococcus aureus (GISA). In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario, Canada: American Society for Microbiology, 2000, p. 56.

    Google Scholar 

  40. Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristinresistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001; 39: 3586 - 3590.

    Article  PubMed  CAS  Google Scholar 

  41. Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000; 37: 57 - 62.

    Article  PubMed  CAS  Google Scholar 

  42. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious Gram-positive infections. Drugs 1999; 58: 1061 - 1097.

    Article  PubMed  CAS  Google Scholar 

  43. Roychoudhury S, Catrenich CE, McIntosh EJ, et al. Quinolone resistance in staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates. Antimicrob Agents Chemother 2001; 45: 1115 - 1120.

    Article  PubMed  CAS  Google Scholar 

  44. Tanaka M, Wada N, Kurosaka SM, Chiba M, Sato K, Hiramatsu K. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. J Antimicrob Chemother 1998; 42: 552 - 553.

    Article  PubMed  CAS  Google Scholar 

  45. Akins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000; 44: 1925 - 1929.

    Article  PubMed  CAS  Google Scholar 

  46. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595 - 2601.

    Article  PubMed  CAS  Google Scholar 

  47. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454 - 459.

    Article  PubMed  CAS  Google Scholar 

  48. Swenson JM, Tenover FC. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2002; 49: 845 - 850.

    Article  PubMed  CAS  Google Scholar 

  49. Steiert M, Schmitz FJ. Dalbavancin (Biosearch Italia/Versicor). Curr Opin Investig Drugs 2002; 3:229-233.

    Google Scholar 

  50. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44: 179 - 192.

    Article  PubMed  CAS  Google Scholar 

  51. Patron RL, Climo MW, Goldstein BP, Archer GL. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 1999; 43: 1754 - 1755.

    PubMed  CAS  Google Scholar 

  52. From the Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. JAMA 1997; 278: 461 - 462.

    Google Scholar 

  53. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998; 27:245-249, quiz 250-251.

    Google Scholar 

  54. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356: 1307 - 1312.

    Article  PubMed  CAS  Google Scholar 

  55. Hageman JC, Pegues DA, Jepson C, et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis 2001; 7: 1023 - 1025.

    Article  PubMed  CAS  Google Scholar 

  56. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46:626-628, 635.

    Google Scholar 

Download references

Authors
  1. A. Peter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Microbiology, Royal Free and University College Medical School, London, England

    Stephen H. Gillespie MD, FRCP, FRCPath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Peter, A., Wilson, R. (2004). Management of Glycopeptide-Resistant Staphylococcus aureus Infections. In: Gillespie, S.H. (eds) Management of Multiple Drug-Resistant Infections. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-738-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-738-3_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-438-8

  • Online ISBN: 978-1-59259-738-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation